SyntheticMR Beheer

Beheer criteriumcontroles 4/4

De CEO SyntheticMR is Ulrik Harrysson, benoemd in Jul2019, heeft een ambtstermijn van 4.75 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 2.28M, bestaande uit 68.9% salaris en 31.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.34% van de aandelen van het bedrijf, ter waarde SEK 3.88M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 3.9 jaar.

Belangrijke informatie

Ulrik Harrysson

Algemeen directeur

SEK 2.3m

Totale compensatie

Percentage CEO-salaris	68.9%
Dienstverband CEO	4.8yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	4.8yrs
Gemiddelde ambtstermijn bestuur	3.9yrs

Recente managementupdates

Recent updates

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Nov 29

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Aug 06

Why SyntheticMR AB (publ) (NGM:SYNT) Could Be Worth Watching

Feb 23

A Look At The Intrinsic Value Of SyntheticMR AB (publ) (NGM:SYNT)

Jan 27

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

Nov 10

Read This Before Selling SyntheticMR AB (publ) (NGM:SYNT) Shares

Mar 09

What Percentage Of SyntheticMR AB (publ) (NGM:SYNT) Shares Do Insiders Own?

Feb 11

SyntheticMR AB (publ) (NGM:SYNT) Insiders Increased Their Holdings

Dec 03

Analyse CEO-vergoeding

Hoe is Ulrik Harrysson's beloning veranderd ten opzichte van SyntheticMR's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2023	SEK 2m	SEK 2m	SEK 10m
Sep 30 2023	n/a	n/a	SEK 6m
Jun 30 2023	n/a	n/a	SEK 6m
Mar 31 2023	n/a	n/a	SEK 7m
Dec 31 2022	SEK 2m	SEK 2m	SEK 6m
Sep 30 2022	n/a	n/a	SEK 8m
Jun 30 2022	n/a	n/a	SEK 7m
Mar 31 2022	n/a	n/a	SEK 2m
Dec 31 2021	SEK 2m	SEK 2m	SEK 8m
Sep 30 2021	n/a	n/a	SEK 8m
Jun 30 2021	n/a	n/a	SEK 5m
Mar 31 2021	n/a	n/a	SEK 3m
Dec 31 2020	SEK 2m	SEK 1m	SEK 663k
Sep 30 2020	n/a	n/a	-SEK 6m
Jun 30 2020	n/a	n/a	-SEK 3m
Mar 31 2020	n/a	n/a	SEK 2m
Dec 31 2019	SEK 2m	SEK 822k	SEK 4m

Compensatie versus markt: De totale vergoeding ($USD 209.02K ) Ulrik } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 236.58K ).

Compensatie versus inkomsten: De vergoeding van Ulrik is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ulrik Harrysson (54 yo)

4.8yrs

Tenure

SEK 2,282,000

Compensatie

Mr. Ulrik Harrysson had been an Independent Director at Qlife Holding AB (publ) since may 5, 2021 until May 2023. He has been the Chief Executive Officer at SyntheticMR AB (publ) since July 1, 2019. He ser...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ulrik Harrysson	Chief Executive Officer	4.8yrs	SEK 2.28m	0.34% SEK 3.9m
Jan Bertus Warntjes	Head of Innovation	6.3yrs	geen gegevens	8.3% SEK 95.8m
Johanna Noren	CFO & Head of Investor Relations	3yrs	geen gegevens	0.0073% SEK 84.2k
Markus Malmgren	Chief Technology Officer	no data	geen gegevens	geen gegevens
Vedran Beglerbegovic	C.P.O	no data	geen gegevens	0.010% SEK 115.8k

4.8yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SYNT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jan Bertus Warntjes	Head of Innovation	17.3yrs	geen gegevens	8.3% SEK 95.8m
Johan Sedihn	Chairman	13.3yrs	SEK 350.00k	4.66% SEK 53.8m
Staffan Persson	Director	11.3yrs	SEK 150.00k	29.31% SEK 338.5m
Ann-Christine Sundell	Director	3.3yrs	SEK 150.00k	0.012% SEK 138.5k
Petra Apell	Director	3.9yrs	SEK 150.00k	0.011% SEK 129.7k
Alex Rovira	Member of Medical Advisory Board	3.4yrs	geen gegevens	geen gegevens
Jeff Miller	Member of Medical Advisory Board	1.8yrs	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SYNT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

SyntheticMR Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

SyntheticMR Announces Appointment of Francois Hebert as New President, North America

SyntheticMR AB (publ) Announces Board Changes

SyntheticMR AB (publ), Annual General Meeting, May 21, 2024

SyntheticMR Appoints Nomination Committee for the 2024 Annual General Meeting

SyntheticMR AB (publ), Annual General Meeting, May 23, 2023

No independent directors

Recent updates

SyntheticMR AB Receives Regulatory Approval for SyMRI 15 in Australia

SyntheticMR AB (publ) to Report Q3, 2024 Results on Nov 19, 2024

SyntheticMR Announces Appointment of Francois Hebert as New President, North America

SyntheticMR Receives Regulatory Approval for Symri in Taiwan

SyntheticMR AB (publ) to Report Q2, 2024 Results on Aug 27, 2024

SyntheticMR AB (publ) Announces Board Changes

SyntheticMR AB (publ) to Report Q1, 2024 Results on May 21, 2024

SyntheticMR AB (publ), Annual General Meeting, May 21, 2024

SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D

SyntheticMR AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking

SyntheticMR Has Submitted Their Next Generation Solution, SyMRI 3D for 510(K) Clearance

SyntheticMR Appoints Nomination Committee for the 2024 Annual General Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

SyntheticMR AB (publ) to Report Nine Months, 2023 Results on Nov 10, 2023

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued after recent price drop

SyntheticMR AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Now 20% undervalued after recent price drop

SyntheticMR Releases A New Update to SyMRI 11.3.11 & 12.1.11

SyntheticMR Introduces Quantitative Neuro Reports to Enhance Clinical Workflow

SyntheticMR Receives Regulatory Approval for Their Innovative SyMRI Software Solution in South Korea

Consensus EPS estimates fall by 28%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Some Investors May Be Worried About SyntheticMR's (NGM:SYNT) Returns On Capital

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

Full year 2022 earnings released: EPS: kr0.15 (vs kr0.20 in FY 2021)

Now 24% undervalued after recent price drop

SyntheticMR AB (publ), Annual General Meeting, May 23, 2023

Consensus EPS estimates fall by 17%

Now 21% undervalued after recent price drop

SyntheticMR AB (publ) to Report Fiscal Year 2022 Results on Feb 15, 2023

Now 20% undervalued after recent price drop

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

No independent directors

Now 21% undervalued after recent price drop

SyntheticMR Receives EU Medical Device Regulation (Mdr) Certificate

SyntheticMR AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

SyntheticMR's SyMRI MSK Software for Knee and Spine Imaging Receives Regulatory Approval in Brazil

Consensus EPS estimates increase by 18%

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

Consensus EPS estimates fall by 14%

Consensus EPS estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

SyntheticMR AB (publ) to Report First Half, 2022 Results on Aug 23, 2022

SyntheticMR's Quantitative MRI Solution Symri Neuro Compatible with Philips Smartspeed to Support Shorter Scan Times

Dr. Jeff Miller Joins SyntheticMR's Medical Advisory Board

SyMRI MSK from SyntheticMR is Now Available on syngo.via Open Apps from Siemens Healthineers

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 19%

Price target decreased to kr36.00

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

SyntheticMR AB (publ), Annual General Meeting, May 10, 2022

SyntheticMR AB (publ) to Report Q1, 2022 Results on May 10, 2022

Now 24% undervalued after recent price drop

Syntheticmr AB (Publ) Announces Net Sales Guidance for the First Quarter 2022

Now 21% undervalued after recent price drop

Full year 2021 earnings: EPS misses analyst expectations

Why SyntheticMR AB (publ) (NGM:SYNT) Could Be Worth Watching

Now 21% undervalued after recent price drop

A Look At The Intrinsic Value Of SyntheticMR AB (publ) (NGM:SYNT)